Johnson & Johnson on Tuesday posted an unexpected fall in quarterly revenue, as a drop in prescription drug sales overshadowed gains in medical devices and consumer products such as Band-Aids.
The diversified health-care company said it earned $2.18 billion (73 cents per share) in the fourth quarter, compared with $1.22 billion (41 cents) a year earlier. The New Brunswick, N.J.-based company’s earnings matched the average forecast of analysts.
